Chandra Sekhar Bathula, Ph.D is currently working as research associate in department of Biomedical Sciences at the Washington State University. He received his M.Sc in Biochemistry from Devi Ahilya University, India and received his Ph.D in Biochemistry and Molecular Biology from University of North Dakota. He pursued his post-doctoral research training in Dr. Adrian Lee laboratory at University of Pittsburgh. He has worked extensively on investigating the growth factor-mediated cell signaling, regulation of cell cycle progression, and cell differentiation (EMT and MET) in breast cancer and tested the efficacy of small molecule inhibitors in combination with chemotherapy on tumor regression in triple negative breast cancer using in vitro and in vivo model systems including patient derived primary xenografts (PDXs). He later moved to Dr. Weimin Li laboratory at the Washington State University and his current research is focused on understanding the role of nuclear PIK3CB signaling in regulation of cell growth and tumorigenesis of breast cancer using 3D in-vitro models and patient derived primary xenografts (PDXs). He works have been published in a series of high impact journals, such as Br J Cancer, Cancer Cell Int., Cancer and Clinical Oncology, Environ Health Perspect, Toxicol Sci., and PLoS One.
Other Editorial Board Members
Shireen Hamid Farhan
Institute for Genetic Engineering and Biotechnologies
View Profile
Sandeep Kumar Kar
Institute of Postgraduate Medical Education and Research
View Profile
Chat with us on WhatsApp
